In Vitro Diagnostic Test for Alzheimer’s Disease Receives Marketing Authorization
The Lumipulse G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic is an FDA-authorized test to aid in the assessment of Alzheimer’s disease.
The Lumipulse G β-Amyloid Ratio (1-42/1-40) in vitro diagnostic is an FDA-authorized test to aid in the assessment of Alzheimer’s disease.
Diadem Srl today announced CE IVD certification for its AlzoSure Predict prognostic blood test for the early prediction of Alzheimer's disease.
Researchers have reported observations that show a link between APOE4 and COVID-19, in terms of susceptibility to SARS-CoV-2 infection and mortality.
Daegu Gyeongbuk Institute of Science and Technology researchers investigated if the APOE4 gene in astrocytes relates to Alzheimer’s disease.
Read MoreScientists in Japan have identified metabolic compounds within the blood that are associated with dementia.
Read MoreDiadem srl has announced results from a retrospective longitudinal study of its AlzoSure Predict prognostic biomarker test for Alzheimer’s.
Read MoreA novel genetic tool has been discovered to identify C9orf72 in FTLD or ALS patients from large population-based cohorts.
Read MoreA study by an international research group identified 15 novel biomarkers that are linked to late-onset dementias.
Read MoreAlzheimer’s disease can be accurately identified in living patients by collecting cerebrospinal fluid using a framework of three biomarkers.
Read MoreLevels of NfL in the blood can identify those who might have neurodegenerative diseases when clinical symptoms are not definitive.
Read MoreUnlike plasma or serum-based assays, PreADx takes an intracellular approach and measures the clearance of beta-amyloid peptides by analyzing a patient’s monocytes.
Read MoreBlood tests show promise in diagnosing Alzheimer’s with less cost and less burdensome procedures, and could be used to identify patients for trials of potential drugs, reports Scientific American.
Read MoreRresearchers provide convincing evidence that an in-house developed blood test for Alzheimer’s disease can detect the disease early and track its course, which has major implications for a potential use in clinical practice and treatment trials.
Read MoreUsing a blood test, a research team has predicted the risk of Alzheimer’s disease in people who were clinically diagnosed as not having Alzheimer’s disease but who perceived themselves as cognitively impaired.
Read MoreResearchers have found new forms of tau protein that become abnormal in the very early stages of Alzheimer’s disease before cognitive problems develop.
Read MoreWhen cleared, the FDA-designated breakthrough device is expected to be among the first commercially available in vitro diagnostics for patients being evaluated for Alzheimer’s disease in the United States.
Read MoreThe new kit provides highly sensitive and efficient approach for studying mitophagy impairment in conditions such as Parkinson’s and Alzheimer’s.
Read MoreBlood plasma levels of p-tau-217 are able to accurately predict amyloid plaques in PET scans, showing promise for a blood test for Alzheimer’s.
Read More